Скачать или смотреть Practice-changing findings in MPNs from ASCO 2025

In this video, Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, briefly comments on the practice-changing findings in the field of myeloproliferative neoplasms (MPNs) from the 2025 ASCO meeting. He highlights the VERIFY trial (NCT05210790), which aims to reduce the need for phlebotomy in patients with polycythemia vera (PV) using the hepcidin mimetic rusfertide, and the SURPASS ET study (NCT04285086), which shows the superiority of ropeginterferon alfa-2b over anagrelide in essential thrombocythemia (ET), offering a new therapeutic option for patients. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.